接种量和异质性万古霉素中介金黄色葡萄球菌（hVISA）对体外药效学模型中万古霉素活性及万古霉素中介金黄色葡萄球菌（VISA）出现的影响
Impact of inoculum size and heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) on vancomycin activity and emergence of VISA in an in vitro pharmacodynamic model.
作者信息
Rose Warren E, Leonard Steven N, Rossi Kerri L, Kaatz Glenn W, Rybak Michael J
机构信息
Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, Michigan 48201, USA.
出版信息
Antimicrob Agents Chemother. 2009 Feb;53(2):805-7. doi: 10.1128/AAC.01009-08. Epub 2008 Nov 17.
Abstract
The activity of vancomycin against heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) and non-hVISA isolates, using an in vitro pharmacodynamic model, was reduced in the presence of a high inoculum amount (10(8) CFU/ml). A high bacterial load of >10(5) CFU/ml persisted for all strains with doses up to 5 g every 12 h against high inoculum amounts. No change in the vancomycin MIC was detected in any isolate at a moderate inoculum amount (10(6) CFU/ml), and bactericidal activity occurred only against the non-hVISA isolate (time to 99% kill, 7.5 h; P = 0.001).
摘要
在体外药效学模型中，当接种量较高（10⁸ CFU/ml）时，万古霉素对异质性万古霉素中介金黄色葡萄球菌（hVISA）和非hVISA菌株的活性降低。对于所有菌株，每12小时给予高达5 g的剂量，针对高接种量，细菌载量>10⁵ CFU/ml持续存在。在中等接种量（10⁶ CFU/ml）下，未检测到任何分离株的万古霉素最低抑菌浓度（MIC）有变化，并且杀菌活性仅针对非hVISA分离株（达到99%杀灭的时间，7.5小时；P = 0.001）。
相似文献
1
Impact of inoculum size and heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) on vancomycin activity and emergence of VISA in an in vitro pharmacodynamic model.接种量和异质性万古霉素中介金黄色葡萄球菌（hVISA）对体外药效学模型中万古霉素活性及万古霉素中介金黄色葡萄球菌（VISA）出现的影响
Antimicrob Agents Chemother. 2009 Feb;53(2):805-7. doi: 10.1128/AAC.01009-08. Epub 2008 Nov 17.
2
Comparative in vitro activity of telavancin, vancomycin and linezolid against heterogeneously vancomycin-intermediate Staphylococcus aureus (hVISA).异质性万古霉素中介金黄色葡萄球菌（hVISA）的体外比较研究：替考拉宁、万古霉素和利奈唑胺的活性。
Int J Antimicrob Agents. 2011 Jun;37(6):558-61. doi: 10.1016/j.ijantimicag.2011.02.007. Epub 2011 Apr 14.
3
Synergistic effect of vancomycin combined with cefotaxime, imipenem, or meropenem against Staphylococcus aureus with reduced susceptibility to vancomycin.万古霉素联合头孢噻肟、亚胺培南或美罗培南对耐万古霉素金黄色葡萄球菌的协同作用。
Turk J Med Sci. 2021 Aug 30;51(4):2150-2158. doi: 10.3906/sag-1910-166.
4
In vitro synergistic effects of various combinations of vancomycin and non-beta-lactams against Staphylococcus aureus with reduced susceptibility to vancomycin.万古霉素与非β-内酰胺类药物不同组合对万古霉素敏感性降低的金黄色葡萄球菌的体外协同作用。
Diagn Microbiol Infect Dis. 2016 Nov;86(3):293-299. doi: 10.1016/j.diagmicrobio.2016.08.009. Epub 2016 Aug 15.
5
Characterization of heterogeneous vancomycin-intermediate resistance, MIC and accessory gene regulator (agr) dysfunction among clinical bloodstream isolates of staphyloccocus aureus.临床金黄色葡萄球菌血流分离株中异质性万古霉素中介耐药、MIC 和辅助基因调节因子（agr）功能障碍的特征。
BMC Infect Dis. 2011 Oct 25;11:287. doi: 10.1186/1471-2334-11-287.
6
Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model.使用体外模型比较头孢比普与万古霉素对耐甲氧西林金黄色葡萄球菌（MRSA）、万古霉素中介金黄色葡萄球菌（VISA）和耐万古霉素金黄色葡萄球菌（VRSA）的药效学活性。
J Antimicrob Chemother. 2009 Aug;64(2):364-9. doi: 10.1093/jac/dkp176. Epub 2009 May 19.
7
In vitro pharmacodynamics of human simulated exposures of ceftaroline and daptomycin against MRSA, hVISA, and VISA with and without prior vancomycin exposure.体外药效学研究：头孢洛林和达托霉素对耐甲氧西林金黄色葡萄球菌（MRSA）、高耐万古霉素中介金黄色葡萄球菌（hVISA）和万古霉素中介金黄色葡萄球菌（VISA）的人模拟暴露，以及有无先前万古霉素暴露的情况。
Antimicrob Agents Chemother. 2014;58(2):672-7. doi: 10.1128/AAC.01516-13. Epub 2013 Nov 11.
8
Pharmacodynamic effect of clinical vancomycin exposures on cell wall thickness in heterogeneous vancomycin-intermediate Staphylococcus aureus.临床万古霉素暴露对异质性万古霉素中介金黄色葡萄球菌细胞壁厚度的药效学影响。
J Antimicrob Chemother. 2010 Oct;65(10):2149-54. doi: 10.1093/jac/dkq292. Epub 2010 Aug 6.
9
Detection of Staphylococcus aureus isolates with heterogeneous intermediate-level resistance to vancomycin in the United States.美国耐万古霉素异质性中间水平金黄色葡萄球菌分离株的检测。
J Clin Microbiol. 2011 Dec;49(12):4203-7. doi: 10.1128/JCM.01152-11. Epub 2011 Oct 5.
10
Comprehensive identification of mutations responsible for heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA)-to-VISA conversion in laboratory-generated VISA strains derived from hVISA clinical strain Mu3.对源自异质性万古霉素中介金黄色葡萄球菌（hVISA）临床菌株Mu3的实验室诱导VISA菌株中导致hVISA向VISA转化的突变进行全面鉴定。
Antimicrob Agents Chemother. 2013 Dec;57(12):5843-53. doi: 10.1128/AAC.00425-13. Epub 2013 Sep 9.
引用本文的文献
1
Between a Rock and a Hard Place: Percutaneous Aspiration and Debulking for Tricuspid Valve Endocarditis.进退两难：经皮抽吸及减容术治疗三尖瓣心内膜炎
Cureus. 2022 May 20;14(5):e25166. doi: 10.7759/cureus.25166. eCollection 2022 May.
2
Comparison of in vitro static and dynamic assays to evaluate the efficacy of an antimicrobial drug combination against Staphylococcus aureus.比较体外静态和动态测定法评估抗金黄色葡萄球菌药物组合的疗效。
PLoS One. 2019 Jan 23;14(1):e0211214. doi: 10.1371/journal.pone.0211214. eCollection 2019.
3
AngioVac System Used for Vegetation Debulking in a Patient with Tricuspid Valve Endocarditis: A Case Report and Review of the Literature.AngioVac系统用于三尖瓣心内膜炎患者的赘生物减容：一例病例报告及文献综述
Case Rep Cardiol. 2017;2017:1923505. doi: 10.1155/2017/1923505. Epub 2017 Nov 7.
4
Optimization of Synergistic Combination Regimens against Carbapenem- and Aminoglycoside-Resistant Clinical Pseudomonas aeruginosa Isolates via Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling.通过基于机制的药代动力学/药效学模型优化针对耐碳青霉烯类和氨基糖苷类的临床铜绿假单胞菌分离株的协同联合治疗方案。
Antimicrob Agents Chemother. 2016 Dec 27;61(1). doi: 10.1128/AAC.01011-16. Print 2017 Jan.
5
Sequential Evolution of Vancomycin-Intermediate Resistance Alters Virulence in Staphylococcus aureus: Pharmacokinetic/Pharmacodynamic Targets for Vancomycin Exposure.万古霉素中介耐药性的序贯演变改变金黄色葡萄球菌的毒力：万古霉素暴露的药代动力学/药效学靶点
Antimicrob Agents Chemother. 2015 Dec 28;60(3):1584-91. doi: 10.1128/AAC.02657-15.
6
Vancomycin and maltodextrin affect structure and activity of Staphylococcus aureus biofilms.万古霉素和麦芽糊精会影响金黄色葡萄球菌生物膜的结构和活性。
Biotechnol Bioeng. 2015 Dec;112(12):2562-70. doi: 10.1002/bit.25681. Epub 2015 Sep 2.
7
Clinical Outcomes in Patients with Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Bloodstream Infection.异质性万古霉素中介金黄色葡萄球菌血流感染患者的临床结局
Antimicrob Agents Chemother. 2013 Sep;57(9):4252-4259. doi: 10.1128/AAC.00380-13. Epub 2013 Jun 24.
8
Vancomycin AUC/MIC ratio and 30-day mortality in patients with Staphylococcus aureus bacteremia.万古霉素 AUC/MIC 比值与金黄色葡萄球菌菌血症患者 30 天死亡率的关系。
Antimicrob Agents Chemother. 2013 Apr;57(4):1654-63. doi: 10.1128/AAC.01485-12. Epub 2013 Jan 18.
9
Synergy between vancomycin and nafcillin against Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model.万古霉素与萘夫西林对金黄色葡萄球菌的体外药代动力学/药效学模型协同作用。
PLoS One. 2012;7(7):e42103. doi: 10.1371/journal.pone.0042103. Epub 2012 Jul 24.
10
Current and novel antibiotics against resistant Gram-positive bacteria.当前和新型抗生素治疗耐药革兰阳性菌感染。
Infect Drug Resist. 2008;1:27-44. doi: 10.2147/idr.s3545. Epub 2008 Sep 9.
本文引用的文献
1
Prevalence and characteristics of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia in a tertiary care center.三级医疗中心中异质性耐万古霉素金黄色葡萄球菌菌血症的患病率及特征
J Clin Microbiol. 2007 May;45(5):1511-4. doi: 10.1128/JCM.01262-06. Epub 2007 Mar 7.
2
A multicenter study evaluating the current strategies for isolating Staphylococcus aureus strains with reduced susceptibility to glycopeptides.一项评估当前分离对糖肽类药物敏感性降低的金黄色葡萄球菌菌株策略的多中心研究。
J Clin Microbiol. 2007 Feb;45(2):329-32. doi: 10.1128/JCM.01508-06. Epub 2006 Nov 15.
3
Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model.在体外药效学模型中，高接种量金黄色葡萄球菌对萘夫西林、万古霉素、利奈唑胺和达托霉素单独及与庆大霉素联合使用时活性的影响。
Antimicrob Agents Chemother. 2004 Dec;48(12):4665-72. doi: 10.1128/AAC.48.12.4665-4672.2004.
4
Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections.万古霉素及其他抗菌药物在金黄色葡萄球菌下呼吸道感染患者中的药效学
Clin Pharmacokinet. 2004;43(13):925-42. doi: 10.2165/00003088-200443130-00005.
5
Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility.对万古霉素敏感性降低的耐甲氧西林金黄色葡萄球菌引起的严重感染的治疗结果。
Clin Infect Dis. 2004 Feb 15;38(4):521-8. doi: 10.1086/381202. Epub 2004 Jan 29.
6
Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus.与异质性万古霉素中介金黄色葡萄球菌所致菌血症相关的临床特征。
Clin Infect Dis. 2004 Feb 1;38(3):448-51. doi: 10.1086/381093. Epub 2004 Jan 12.
7
Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin.耐万古霉素异质性金黄色葡萄球菌菌株在日本医院的传播。
Lancet. 1997 Dec 6;350(9092):1670-3. doi: 10.1016/S0140-6736(97)07324-8.
Zotero 插件